

A Practice Tool for Combined Hormonal Contraceptives DOCUMENTATION

Development Team (Practice Tool):

Nese Yuksel, PharmD¹
Anne Marie Whelan, PharmD²
Christine Maslanko, BScPharm¹

Development Team (Documentation Tool):

Nese Yuksel, PharmD¹
Andrea Jokic, PharmD¹

¹ Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB
² College of Pharmacy, Dalhousie University, Halifax, NS



Patient Information

NAME: DATE OF APPOINTMENT:

TELEPHONE: EXT. DATE OF BIRTH:

STEP 1: Assess if CHC is Appropriate

Gather Patient History

AGE: MEDICAL HISTORY:

WEIGHT: HEIGHT:

Smoking history

Do you currently smoke? Yes No

If yes, how many cigarettes do you smoke per day?

Screen for contraindications

<input type="checkbox"/> Smokes ≥ 15 cigarettes/day and over the age of 35 years	<input type="checkbox"/> Migraines with aura	<input type="checkbox"/> Breast Cancer – current or past history	<input type="checkbox"/> Rheumatic diseases such as lupus
<input type="checkbox"/> Cardiovascular disease	<input type="checkbox"/> Diabetes with microvascular complications	<input type="checkbox"/> Active or past liver disease	<input type="checkbox"/> Other active cancers/chemotherapy
<input type="checkbox"/> Hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg)	<input type="checkbox"/> VTE – current or past history	<input type="checkbox"/> Given birth in the last 3 weeks	<input type="checkbox"/> Undiagnosed abnormal uterine bleeding
<input type="checkbox"/> History of stroke	<input type="checkbox"/> Thrombophilia	<input type="checkbox"/> Breastfeeding <6 weeks postpartum	

Screen for drug interactions

<input type="checkbox"/> Anticonvulsants (phenytoin, carbamazepine, primidone, topiramate, phenobarbital, oxcarbazepine)	<input type="checkbox"/> Rifampin	<input type="checkbox"/> St John's Wort
	<input type="checkbox"/> Antiretrovirals (efavirenz, nevirapine, ritonavir)	<input type="checkbox"/> Lamotrigine (EE can induce metabolism)

Menstrual history

When was your last menstrual period?

How often do you get your periods? (ie. every 28 days)

Are your periods Regular or Irregular

Are your periods heavy? Yes No AND/OR

Do you get spotting in between periods? Yes No

If yes to spotting or heavy periods, has it been assessed? Yes No

COMMENTS

Past & current contraceptive use

What type of contraception are you currently using?

Have you been on hormonal contraceptives in the past? Yes No

If yes, which ones and for how long?

Did you have any side effects? Yes No

If yes, please describe:

Were you satisfied with past contraceptives? Yes No

Why or why not?

Were you able to remember to take your contraceptive? Yes No

STEP 1: Assess if CHC is Appropriate

Other reasons for CHC use

Possibility of pregnancy

Have you had unprotected intercourse since your last menstrual period?

Yes No

Is there a possibility of pregnancy? If yes, recommend pregnancy test.

Yes No

Assess if LARC is appropriate

Do you want to become pregnant in the next year? Yes No

How important is it for you not to be pregnant right now? Very important Not that important

Would you be interested in using a LARC?* Yes No

* If interested in LARC → Refer.

Perform blood pressure measurement

Blood pressure measurement mmHg

Refer if any of the following

BP is \geq 140/90 mmHg

Abnormal uterine bleeding

Potential for drug interaction(s)

Smoker and over 35 years

One or more contraindications listed above

Possibility of pregnancy

Assessment

STEP 2: Initiate a CHC Product

Plan

- Prescribe
- Refer to primary care provider
- Make a recommendation

COMMENTS

Prescription (if applicable)

Product name and strength:

Choose a regimen:

- Cyclic (21/7)
- Shortened HFI (24/4)
- Extended cycle
- Continuous dosing

Amount prescribed:

Refills:

STEP 3: Patient Education for CHC

Patient education provided (see patient education checklist or practice tool for details)

Yes No

COMMENTS

Follow-up plan

Next follow-up:

- 1 month
- 3 months
- Next refill

Method:

- Telephone call
- In-person

COMMENTS

Pharmacist

Follow-up Monitoring of CHC

NAME: DATE OF FOLLOW-UP:
TELEPHONE: EXT. DATE OF BIRTH:

Assess patient satisfaction

(How do you like your current method of contraception?)

Ask about side effects

 Have you experienced any of the following side effects?

Breakthrough bleeding Water retention Mood changes Weight gain
 Nausea Headache Acne Other:

Check adherence

Check if changes with health status

(ie change in medical conditions/medications, smoking status, weight)

Yes No and if yes, please describe

Perform blood pressure measurement

Blood pressure measurement mmHg

Refer if any of the following:

Side effects Abnormal uterine bleeding Contraindications Other:
 BP \geq 140/90mmHg Adherence issues Interested in LARC

Assessment

Plan

Continue current CHC
 Change to a different CHC
 Refer

Manage side effect
 Other recommendation:

COMMENTS

Prescription (if applicable)

Product name and strength:

Choose a regimen:

Cyclic (21/7) Shortened HFI (24/4)
 Extended cycle Continuous dosing

Amount prescribed:

Refills:

Follow-up Plan

Next follow-up:

1 month
 3 months
 Next refill

Method:

Telephone Call
 In-person

COMMENTS

Pharmacist

PATIENT EDUCATION CHECKLIST WHEN STARTING COMBINED HORMONAL CONTRACEPTIVES

This checklist includes the general information to provide to patients when starting combined hormonal contraceptives (CHC):

How to use CHC

When to start CHC (quick start is recommended method)

When contraceptive efficacy starts

How long to use back-up contraception when starting (for example 7 days after starting)

Tips to help remember CHC

What to do when CHC dose is missed or delayed

Common side effects and management strategies

Safe sex practices regarding STI prevention

When to seek medical attention

Development Team (Practice Tool):

Nese Yuksel, PharmD¹

Anne Marie Whelan, PharmD²

Christine Maslanko, BScPharm¹

NOVEMBER 2023

Corresponding author nese.yuksel@ualberta.ca

© 2023. All rights reserved.

Development Team (Documentation Tool):

Nese Yuksel, PharmD¹

Andrea Jokic, PharmD¹

¹ Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB • ² College of Pharmacy, Dalhousie University, Halifax, NS

Funding for this project was provided by the Canadian Society of Hospital Pharmacists (CSHP) Foundation Education Grant.